NO20011282L - Nytt influensavirusvaksinepreparat - Google Patents

Nytt influensavirusvaksinepreparat

Info

Publication number
NO20011282L
NO20011282L NO20011282A NO20011282A NO20011282L NO 20011282 L NO20011282 L NO 20011282L NO 20011282 A NO20011282 A NO 20011282A NO 20011282 A NO20011282 A NO 20011282A NO 20011282 L NO20011282 L NO 20011282L
Authority
NO
Norway
Prior art keywords
influenza virus
virus vaccine
vaccine preparation
new influenza
mug
Prior art date
Application number
NO20011282A
Other languages
English (en)
Other versions
NO20011282D0 (no
Inventor
Otfried Kistner
Noel Barrett
Wolfgang Mundt
Friedrich Dorner
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3515932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20011282(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of NO20011282D0 publication Critical patent/NO20011282D0/no
Publication of NO20011282L publication Critical patent/NO20011282L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20011282A 1998-09-15 2001-03-14 Nytt influensavirusvaksinepreparat NO20011282L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0155598A AT408615B (de) 1998-09-15 1998-09-15 Neue influenzavirus-impfstoffzusammensetzung
PCT/AT1999/000223 WO2000015251A2 (de) 1998-09-15 1999-09-14 Influenzavirus-impfstoffzusammensetzung

Publications (2)

Publication Number Publication Date
NO20011282D0 NO20011282D0 (no) 2001-03-14
NO20011282L true NO20011282L (no) 2001-05-14

Family

ID=3515932

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011282A NO20011282L (no) 1998-09-15 2001-03-14 Nytt influensavirusvaksinepreparat

Country Status (11)

Country Link
US (1) US6372223B1 (no)
EP (1) EP1113816B1 (no)
JP (1) JP2003523310A (no)
AT (2) AT408615B (no)
AU (1) AU763210B2 (no)
DE (1) DE59913046D1 (no)
DK (1) DK1113816T3 (no)
ES (1) ES2257072T3 (no)
HU (1) HUP0103908A3 (no)
NO (1) NO20011282L (no)
WO (1) WO2000015251A2 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7494659B2 (en) 2000-09-25 2009-02-24 Polymun Scientific Immunbiologische Forschung Gmbh Live attenuated influenza vaccine
WO2003002069A2 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
KR100597699B1 (ko) * 2003-01-30 2006-07-07 학교법인 포항공과대학교 면역원성이 증강된 ｄｎａ 백신 조성물
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
AU2004249802B2 (en) 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
WO2005074460A2 (en) * 2003-12-05 2005-08-18 Becton Dickinson And Company Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
CA2562932A1 (en) * 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine
JP4650798B2 (ja) * 2004-04-19 2011-03-16 デンカ生研株式会社 ウイルスの生産方法
JP2008512443A (ja) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
EP2923711A1 (en) 2004-11-03 2015-09-30 Novartis Vaccines and Diagnostics, Inc. Influenza vaccination
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
PT1861120T (pt) * 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
WO2007052060A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
ES2420829T3 (es) * 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
GB0522601D0 (en) * 2005-11-04 2005-12-14 Chiron Srl Adjuvanted influenza vaccines and kits
EP1951298A1 (en) * 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
EP3753574A1 (en) 2006-01-27 2020-12-23 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
HRP20140488T1 (hr) 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Cjepivo protiv influence
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
SG178761A1 (en) * 2007-02-07 2012-03-29 Sigma Tau Ind Farmaceuti Recombinant antigens of human cytomegalovirus (hcmv)
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
MY172788A (en) 2008-08-01 2019-12-12 Gamma Vaccines Pty Ltd Influenza vaccines
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011041847A1 (en) 2009-10-09 2011-04-14 Cbio Limited Chaperonin 10 variants
CA2780207A1 (en) 2009-11-18 2011-05-26 Auburn University Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
US9657359B2 (en) 2010-09-07 2017-05-23 Novartis Ag Generic assays for detection of mamalian reovirus
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
WO2013138863A1 (en) 2012-03-23 2013-09-26 Newsouth Innovations Pty Limited Kinase inhibitors for the treatment of cancer
WO2013181696A1 (en) 2012-06-05 2013-12-12 The Australian National University Vaccination with interleukin-4 antagonists
PL2880014T3 (pl) 2012-08-06 2017-10-31 Pitney Pharmaceuticals Pty Ltd Związki do leczenia chorób związanych ze szlakiem mTOR
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
CA2895149C (en) 2012-12-17 2023-08-22 Pitney Pharmaceuticals Pty Limited Treatment of diseases involving mucin
WO2014100857A1 (en) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US20150166255A1 (en) * 2013-12-12 2015-06-18 ASCLEMED USA, INC. dba EnovaChem Manufacturing Vitamin b-12 injection kit
CN106232106B (zh) 2014-04-18 2020-08-11 奥本大学 用于诱导先天性和适应性免疫力的颗粒状疫苗制剂
US10293044B2 (en) 2014-04-18 2019-05-21 Auburn University Particulate formulations for improving feed conversion rate in a subject
CN107427569B (zh) 2015-03-26 2022-12-30 Gpn疫苗有限公司 链球菌疫苗
MX2019011599A (es) 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI945483A7 (fi) * 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
ES2378409T3 (es) * 1994-11-10 2012-04-12 Baxter Healthcare S.A. Método para producir sustancias biológicas en cultivo sin proteínas
FR2754715B1 (fr) * 1996-10-18 1998-11-13 Seppic Sa Adjuvant, notamment sous forme d'une emulsion contenant un cation metallique trivalent et composition vaccinale le comprenant
US5795582A (en) 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers

Also Published As

Publication number Publication date
DK1113816T3 (da) 2006-04-03
HUP0103908A3 (en) 2003-10-28
ES2257072T3 (es) 2006-07-16
ATA155598A (de) 2001-06-15
AT408615B (de) 2002-01-25
AU763210B2 (en) 2003-07-17
HK1038507A1 (en) 2002-03-22
US6372223B1 (en) 2002-04-16
ATE315404T1 (de) 2006-02-15
JP2003523310A (ja) 2003-08-05
WO2000015251A2 (de) 2000-03-23
EP1113816B1 (de) 2006-01-11
HUP0103908A2 (hu) 2002-02-28
WO2000015251A3 (de) 2000-08-24
DE59913046D1 (de) 2006-04-06
EP1113816A2 (de) 2001-07-11
NO20011282D0 (no) 2001-03-14
AU5720099A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
NO20011282L (no) Nytt influensavirusvaksinepreparat
EP1618889B8 (en) Influenza Vaccine
UA85536C2 (en) Viral antigens
ATE298580T1 (de) Eigenschaften von poly(amidoamine) dendrimeren als adjuvantien
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
AU2002355677A1 (en) Antigenic polypeptides
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
BR9906927A (pt) Proteìnas de neisseria meningitidis
MY133780A (en) Vaccine composition
WO2004062597A3 (en) Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
ZA956797B (en) Method for preparing influenza virus, antigens obtained and the applications.
DK0745387T3 (da) Adjuvanser til virale vacciner
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
GB9818133D0 (en) Vaccine
CO5050367A1 (es) Nueva composicion
ATE374622T1 (de) Genetische impstoffe mit adjuvans
DK1401492T3 (da) LTB4 som vaccineadjuvans
WO2002077648A3 (en) Pathogenic and commensal vaccine antigens
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
IT1318400B1 (it) Markers di massa molecolare per westner blot.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application